Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer
Life · 22.12.2023 · 14 (1) · 22
DOI: 10.3390/life14010022 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 22.12.2023. Verfasst von Christos Cortas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Bank of Cyprus Oncology Centre, Nicosia 2006, Cyprus. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Patients with differentiated thyroid cancer usually present with early-stage disease and undergo surgery followed by adjuvant radioactive iodine ablation, resulting in excellent clinical outcomes and prognosis. However, a minority of patients relapse with metastatic disease, and eventually develop radioactive iodine refractory disease (RAIR). In the past there were limited and ineffective options for systemic therapy for RAIR, but over the last ten to fifteen years the emergence of tyrosine kinase inhibitors (TKIs) has provided important new avenues of treatment for these patients, that are the focus of this review. Currently, Lenvatinib and Sorafenib, multitargeted TKIs, represent the standard first-line systemic treatment options for RAIR thyroid carcinoma, while Cabozantinib is the standard second-line treatment option. Furthermore, targeted therapies for patients with specific targetable molecular abnormalities include Latrectinib or Entrectinib for patients with NTRK gene fusions and Selpercatinib or Pralsetinib for patients with RET gene fusions. Dabrafenib plus Trametinib currently only have tumor agnostic approval in the USA for patients with BRAF V600E mutations, including thyroid cancer. Redifferentiation therapy is an area of active research, with promising initial results, while immunotherapy studies with checkpoint inhibitors in combination with tyrosine kinase inhibitors are underway.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Department, Bank of Cyprus Oncology Centre, Nicosia 2006, Cyprus.
ORCID-Profile: Christos Cortas
Zitieren
APA
Cortas, C., & Charalambous, H. (2023). Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer. Life, 14(1), 22. https://doi.org/10.3390/life14010022
Vancouver
Cortas C, Charalambous H. Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer. Life. 2023;14(1):22. doi:10.3390/life14010022
BibTeX
@article{Cortas2023,
author = {Cortas, Christos and Charalambous, Haris},
title = {Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer},
journal = {Life},
year = {2023},
volume = {14},
number = {1},
pages = {22},
doi = {10.3390/life14010022}
}
EUVIMED